Chondromyxoid fibroma of the mandible: A case report Elseyoufi, Mohamed; Coleman, Hedley; Tsakiris, Peter
Advances in oral and maxillofacial surgery,
January-March 2021, 2021-01-00, 2021-01-01, Letnik:
1
Journal Article
Recenzirano
Odprti dostop
Chondromyxoid fibroma (CMF) is a rare, benign neoplasm of bone, accounting for less than.
2% of bone tumors. A CMF of the mandible is reported in a 43 old year man incidentally discovered during a ...routine dental examination. It presented as a well-defined irregular unilocular radiolucent lesion in the right of the mandible and was removed surgically with no post-operative complications.
Case Presentation Chondromyxoid fibroma (CMF) is a relatively rare bone tumor of cartilaginous origin and it comprises less than 1% of all primary bony tumors. Clavicle is an unusual site of ...involvement for any bone tumor and may produce diagnostic dilemma. Approximately only 1% of all primary bone tumors may involve the clavicle. The literature on clinical features and outcome of CMF clavicle remains sparse. Conclusion We present an unusual case of CMF clavicle in which the medial aspect of the clavicle gradually disappeared on radiographs. CMF should be included in the differential diagnoses of disappearing bone disease.
Introduction: Chondromyxoid fibroma is a rare benign tumor with aggressive behavior accounting for less than 0.5% of all bone tumors. There are several case-reports of this tumor occurring in ...different bones. Case report: Here we report a case of 19 years old male with the tumor arising from the inferior pole of right patella which was treated by complete excision of the lesion. The histopathology report was consistent with chondromyxoid fibroma. Conclusion: Chondromyxoid fibroma is a benign but locally aggressive tumor which may occur at unusual sites.
Chondromyxoid fibroma is a rare bone tumor with cartilaginous differentiation which presents less than 1% of bone tumors. It is a benign lesion and occurs in the fibula in less than 10% of the cases. ...A 25-year-old with no medical history, right-hander, and long-distance running athlete who consulted in our orthopedic department for right ankle pain. This symptom dates back to 6 weeks and considerably hampered his professional sports activities. This mechanical ankle pain is next to the external malleolus without irradiation and subsides with usual analgesics. The clinical examination was poor. There was no swelling. Bony landmarks were painless. Motion range was normal. The neurovascular exam did not find any abnormalities. X-rays showed a rounded and well-defined lytic bone lesion located in the external malleolus and classified Lodwick Ia (A,B). Due to the benign aspect, we decided to perform an excisional biopsy with a cancellous autograft. The gesture was performed by a lateral approach under loco-regional anesthesia. The graft was taken from the proximal tibial epiphysis through a small internal incision. The patient resumed his training after 2 months, and returned to his professional sports level after 3 months. At the last follow-up of 6 months, the patient had not reported any symptoms and the radiological control was satisfying (C,D).
Chondromyxoid fibroma (CMF) is a rare benign bone neoplasm that manifests histologically as a lobular proliferation of stellate to spindle-shaped cells in a myxoid background, exhibiting morphologic ...overlap with other cartilaginous and myxoid tumors of bone. CMF is characterized by recurrent genetic rearrangements that place the glutamate receptor gene GRM1 under the regulatory control of a constitutively active promoter, leading to increased gene expression. Here, we explore the diagnostic utility of GRM1 immunohistochemistry as a surrogate marker for GRM1 rearrangement using a commercially available monoclonal antibody in a study of 230 tumors, including 30 CMF cases represented by 35 specimens. GRM1 was positive by immunohistochemistry in 97% of CMF specimens (34/35), exhibiting moderate to strong staining in more than 50% of neoplastic cells; staining was diffuse (>95% of cells) in 25 specimens (71%). Among the 9 CMF specimens with documented exposure to acid decalcification, 4 (44%) exhibited diffuse immunoreactivity (>95%) for GRM1, whereas all 15 CMF specimens (100%) with lack of exposure to decalcification reagents were diffusely immunoreactive ( P =0.003). High GRM1 expression at the RNA level was previously observed by quantitative reverse transcription polymerase chain reaction in 9 CMF cases that were also positive by immunohistochemistry; low GRM1 expression was observed by quantitative reverse transcription polymerase chain reaction in the single case of CMF that was negative by immunohistochemistry. GRM1 immunohistochemistry was negative (<5%) in histologic mimics of CMF, including conventional chondrosarcoma, enchondroma, chondroblastoma, clear cell chondrosarcoma, giant cell tumor of the bone, fibrous dysplasia, chondroblastic osteosarcoma, myoepithelial tumor, primary aneurysmal bone cyst, brown tumor, phosphaturic mesenchymal tumor, CMF-like osteosarcoma, and extraskeletal myxoid chondrosarcoma. These results indicate that GRM1 immunohistochemistry may have utility in distinguishing CMF from its histologic mimics.
The clinical, radiological, and histopathological features of chondromyxoid fibroma can sometimes resemble those of other benign or malignant tumors. Recently, recurrent
rearrangements have been ...identified in chondromyxoid fibroma, and GRM1 positivity by immunohistochemistry has emerged as a dependable surrogate marker for this molecular alteration. Phosphaturic mesenchymal tumor is a rare tumor that often exhibits overexpression of fibroblastic growth factor 23 (FGF23) through various mechanisms. In this report, we present a case of
-rearranged chondromyxoid fibroma that also exhibited FGF23 expression via in situ hybridization, posing significant diagnostic challenges during workup of the initial core biopsy. We hope that this case can serve as an educational resource, shedding light on a rare diagnostic pitfall.
Chondromyxoid fibroma-like osteosarcoma (CMF-OS) is an exceedingly rare subtype of low-grade central osteosarcoma (LGCO), accounting for up to 10% of cases and making it difficult to diagnose. CMF-OS ...is frequently misdiagnosed on a radiological examination and biopsy, even after the initial operation. Its treatment is a controversial issue due to its low-grade classification and actual high-grade behavior.
We retrospectively reviewed the medical charts of more than 2000 osteosarcoma patients between 2008 and 2019; 11 patients with CMF-OS were identified, of which six patients were treated by our institution with complete clinical characteristics, including treatment and prognosis, radiological and pathological features were reviewed. Three males and three females with a median age of 46 (range 22-56) years were pathologically proven to have CMF-OS. The radiological presentation of CMF-OS is variable, thus radiological misdiagnoses are common. However, one must not ignore a malignant radiologic appearance. The most distinctive pathological feature conferring the diagnosis of CMF-OS is the presence of osteoid production directly by the tumor cells under a chondromyxoid fibroma (CMF)-like background. Differential diagnoses based on comprehensive data from CMF, LGCO, chondrosarcoma (CHS), conventional osteosarcoma (COS), etc., are needed. All patients were treated with an operation and chemotherapy, and one patient received additional radiotherapy. Nevertheless, recurrence and metastasis are common in CMF-OS patients. Relatively invasive biological behavior of CMF-OS is against the low-grade classification of this disease.
It is important to recognize CMF-OS and distinguish it from CMF, CHS, COS and other LGCOs. CMF-OS has a relatively poor prognosis despite its low-grade classification.
Celotno besedilo
Dostopno za:
DOBA, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK
Chondromyxoid fibroma (CMF) is a very rare case usually appears around the knee. CMF presented high recurrence rate 25% among treated cases. However, in this case, interestingly CMF in the right ...upper arm was radiologically and pathologically diagnosed. It measures a 6.9 mm × 1.7 mm lesion.
36-year-old male showed CMF in the juxtacortic proximal humerus. Computed tomography (CT) and magnetic resonance imaging (MRI) of the right upper arm interestingly presented an expansile, mildly lobulated, septate lesion a 6.9 mm × 1.7 mm. Pathological analysis of biopsy showed a bony tissue consisting of cartilaginous, fibrous and myxoid stroma with abundant stellate shaped cells that present vary nucleus size and a minority of nuclear division. Surgical allogeneic bone graft and plate internal fixation was performed after the intralesional curettage surgery. Postoperation the patient was received doxorubicin 50–75 mg/m2 21 days cycle. Results showed that the intralesional curettage surgery of CMF, allogeneic bone graft and plate internal fixation combined with doxorubicin was successfully treated CMF and efficiently prevent relapse during 20 months of observations.
the juxtacortic CMF was unusually diagnosed in the proximal humerus, it has been efficiently eliminated by a surgical operation and doxorubicin 50–75 mg/m2 that prevented tumor recurrence.
•Juxtacortic Chondromyxoid Fibroma was diagnosed in the Proximal Humerus.•Surgical tumor enucleation followed by plate internal fixation.•Tumor tissue consisted of cartilaginous, fibrous and myxoid stroma in lobular structure.
Phosphaturic mesenchymal tumor (PMT) is a rare neoplasm that causes tumor-induced osteomalasia (TIO) in most affected patients, usually through the production of fibroblast growth factor 23 (FGF23). ...This tumor is often misdiagnosed due to its relative rarity and its widely varied histomorphologic spectrum. Here we describe a case of a 78-year-old woman who presented with a left middle tumor without symptoms of TIO. The histological features resembled chondromyxoid fibroma with smudgy calcification in the tumor matrix. In addition, we evaluated FGF23 expression through immunohistochemical study and reverse transcription polymerase chain reaction. PMT with chondromyxoid fibroma features are extremely rare. Examining the expression of FGF23 is useful in the diagnosis of PMT.
Craniofacial chondromyxoid fibromas (CMFs) are a rare benign tumor of cartilaginous origin. They are commonly misdiagnosed due to the paucity of information on tumor characteristics. We performed a ...systematic review to characterize CMFs located in different regions of the craniofacial skeleton.
A search of the literature was executed using the search phrase “chondromyxoid fibroma” and included articles from 1990–2020. Sixty-eight articles met the inclusion criteria, with a total of 91 patients with analyzable data (22 with calvarial and 69 with sinonasal tumor locations). Descriptive analyses were performed to compare pre-selected characteristics between the 2 groups.
Sinonasal CMF frequently presented with cranial nerve palsy and expectedly had a high rate of nasal symptoms. Calvarial tumors frequently presented with an external mass and headache. Gross total resection (GTR) was achieved in a higher proportion of cases in the calvarial group versus the sinonasal group (83.3% vs. 53.1%). Overall recurrence rate at 17.7% was higher in sinonasal CMF compared with the calvarial tumors at 8.3%. Recurrences after GTR were similar in the sinonasal and calvarial groups (9.7% vs. 9.1%). In patients who did not achieve GTR, recurrence was higher in the sinonasal compared with the calvarial group (27.6% vs. 0%).
Craniofacial CMF in calvarial and sinonasal locations have distinct clinical characteristics and response to treatment. Sinonasal lesions tend to have higher recurrence compared to calvarial CMF. Performance of GTR is associated with decreased recurrence in all CMFs.
PDF
